Inhibikase Therapeutics financials
$2.02−1.46%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.00 | $79.6K |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.00 | $79.6K |
| Gross margin | — | — | — | — | — | — | — | — | — | — | 100.0% | 100.0% |
| Operating income | -$21.1M | -$17.8M | -$13.8M | -$12.8M | -$10.8M | -$14.6M | -$12.9M | -$5.8M | -$5.1M | -$4.8M | -$4.4M | -$4.8M |
| Net income | -$19.6M | -$16.4M | -$12.7M | -$11.9M | -$9.9M | -$13.7M | -$12.1M | -$5.8M | -$5.0M | -$4.6M | -$4.2M | -$4.6M |
| Net margin | — | — | — | — | — | — | — | — | — | — | −417794000.0% | −5775.1% |
| Diluted EPS | $-0.11 | $-0.10 | $-0.10 | $-0.13 | $-0.11 | $-0.15 | $-0.17 | $-0.65 | $-0.66 | $-0.73 | $-0.51 | $-0.75 |
| EBITDA | -$21.1M | -$17.8M | -$13.8M | -$12.7M | -$10.8M | -$14.6M | -$12.9M | -$5.8M | -$5.0M | -$4.8M | -$4.4M | -$4.8M |
| Operating cash flow | -$12.4M | -$12.1M | -$7.5M | -$10.6M | -$5.6M | -$4.1M | -$5.3M | -$4.9M | -$5.1M | -$3.9M | -$3.4M | -$4.1M |
| Free cash flow | -$12.4M | -$12.1M | -$7.5M | -$10.6M | -$5.6M | -$4.1M | -$5.3M | -$4.9M | -$5.1M | -$3.9M | -$3.4M | -$4.1M |
| Diluted shares | 174.6M | 172.3M | 123.6M | 90.1M | 90.0M | 89.5M | 72.1M | 8.9M | 7.5M | 6.3M | 8.1M | 6.2M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $31.2M | $49.6M | $139.2M | $38.3M | $77.7M | $73.4M |
| Short-term investments | $127.8M | $120.8M | $39.5M | $39.1M | $9.9M | $19.7M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $37.9K | $74.8K |
| Total assets | $163.6M | $173.3M | $181.2M | $79.6M | $88.9M | $94.3M |
| Total liabilities | $10.3M | $5.7M | $8.3M | $6.7M | $8.8M | $8.6M |
| Shareholders' equity | $153.3M | $167.6M | $172.9M | $72.9M | $80.1M | $85.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology